Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect wa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Grard, Soazic, Catho, Gaud, Valour, Florent, Bouaziz, Anissa, Perpoint, Thomas, Braun, Evelyne, Biron, François, Miailhes, Patrick, Ferry, Tristan, Chidiac, Christian, Souquet, Pierre-Jean, Couraud, Sébastien, Lina, Gérard, Goutelle, Sylvain, Veziris, Nicolas, Dumitrescu, Oana, Ader, Florence
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4690547/
https://ncbi.nlm.nih.gov/pubmed/26719846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofv175
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados